Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications

Abstract

A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm 2 wound tissue of Erythropoietin and about 100-300 mg per cm 2 wound tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction or treating ischemia in the subject. Unit dosage forms, pharmaceutical compositions, cosmetic compositions and formulations comprising Erythropoietin and/or Fibronectin are also disclosed.

What is claimed is: 
     
         1 . A method of promoting wound healing or connective tissue reconstruction in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby promoting wound healing or connective tissue reconstruction in the subject. 
     
     
         2 . A method of treating ischemia in a subject in need thereof, the method comprising topically administering to the subject about 10-30 μg per cm 2  tissue of Erythropoietin and about 100-300 μg per cm 2  tissue of Fibronectin, thereby treating ischemia in the subject. 
     
     
         3 . The method of  claim 1 , wherein the connective tissue comprises collagen. 
     
     
         4 . The method of  claim 1 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         5 . The method of  claim 1 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         6 . The method of  claim 1 , further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid. 
     
     
         7 . The method of  claim 1 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         8 . The method of  claim 1 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         9 . The method of  claim 1 , wherein said Erythropoietin and said Fibronectin are in separate formulations. 
     
     
         10 . The method of  claim 2 , wherein a dose of said Erythropoietin is about 20 μg per cm 2  tissue. 
     
     
         11 . The method of  claim 2 , wherein a dose of said Fibronectin is about 200 μg per cm 2  tissue. 
     
     
         12 . The method of  claim 2 , further comprising administering a factor selected from the group consisting of an extracellular matrix component, a growth factor, a hormone, an angiogenic factor, a coagulation factor, a cytokine, a chemokine, an enzyme, a neurotransmitter, a vitamin, a carbohydrate, an ion, an iron chelator, a fatty acid, an antibiotic, and an amino acid. 
     
     
         13 . The method of  claim 2 , wherein said administering of said Erythropoietin and said Fibronectin is effected concomitantly. 
     
     
         14 . The method of  claim 2 , wherein said Erythropoietin and said Fibronectin are in a co-formulation. 
     
     
         15 . The method of  claim 2 , wherein said Erythropoietin and said Fibronectin are in separate formulations. 
     
     
         16 . The method of  claim 1 , wherein the active ingredients administered to said subject consist of Erythropoietin and Fibronectin. 
     
     
         17 . The method of  claim 1 , wherein said administering is effected at least once a day. 
     
     
         18 . A pharmaceutical composition comprising as an active ingredient about 10-30 μg per ml Erythropoietin and about 100-300 μg per ml Fibronectin and a pharmaceutically acceptable carrier or diluent for topical administration.